Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prothena Corp Public (PRTA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Prothena Corp Public (PRTA) over the last 14 years, with Q3 2025 value amounting to $330.8 million.

  • Prothena Corp Public's Cash & Equivalents fell 3628.59% to $330.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.8 million, marking a year-over-year decrease of 3628.59%. This contributed to the annual value of $471.4 million for FY2024, which is 2382.59% down from last year.
  • Per Prothena Corp Public's latest filing, its Cash & Equivalents stood at $330.8 million for Q3 2025, which was down 3628.59% from $371.4 million recorded in Q2 2025.
  • In the past 5 years, Prothena Corp Public's Cash & Equivalents ranged from a high of $710.4 million in Q4 2022 and a low of $330.8 million during Q3 2025
  • Over the past 5 years, Prothena Corp Public's median Cash & Equivalents value was $543.0 million (recorded in 2022), while the average stood at $528.2 million.
  • As far as peak fluctuations go, Prothena Corp Public's Cash & Equivalents surged by 9605.05% in 2021, and later tumbled by 3628.59% in 2025.
  • Quarter analysis of 5 years shows Prothena Corp Public's Cash & Equivalents stood at $579.1 million in 2021, then increased by 22.68% to $710.4 million in 2022, then fell by 12.89% to $618.8 million in 2023, then dropped by 23.83% to $471.4 million in 2024, then decreased by 29.82% to $330.8 million in 2025.
  • Its Cash & Equivalents was $330.8 million in Q3 2025, compared to $371.4 million in Q2 2025 and $417.9 million in Q1 2025.